A randomised, double-blind trial examining the effects of an ACE inhibitor-based blood pressure lowering regimen on the risk of stroke among patients with a history of cerebrovascular disease.
Click here for more list of key publications from the PROGRESS trial
Results showed the treatment reduced risk of stroke by a quarter, and as a result such treatment is now recommended in international guidelines for treatment of hypertension, including the JNC7, WHO-ISH, European and Australian Guidelines, and in major guidelines for stroke management. Results have been published in The Lancet.
6,105 patients, 10 countries, 172 centres